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Brief communicationThe AMPK activator R419 improves exercise
capacity and skeletal muscle insulin sensitivity
in obese miceKatarina Marcinko 1, Adam L. Bujak 1, James S.V. Lally 1, Rebecca J. Ford 1, Tammy H. Wong 1,
Brennan K. Smith 1, Bruce E. Kemp 3, Yonchu Jenkins 4, Wei Li 4, Todd M. Kinsella 4, Yasumichi Hitoshi 4,
Gregory R. Steinberg 1,2,*ABSTRACT
Objective: Skeletal muscle AMP-activated protein kinase (AMPK) is important for regulating glucose homeostasis, mitochondrial content and
exercise capacity. R419 is a mitochondrial complex-I inhibitor that has recently been shown to acutely activate AMPK in myotubes. Our main
objective was to examine whether R419 treatment improves insulin sensitivity and exercise capacity in obese insulin resistant mice and whether
skeletal muscle AMPK was important for mediating potential effects.
Methods: Glucose homeostasis, insulin sensitivity, exercise capacity, and electron transport chain content/activity were examined in wildtype
(WT) and AMPK b1b2 muscle-speciﬁc null (AMPK-MKO) mice fed a high-fat diet (HFD) with or without R419 supplementation.
Results: There was no change in weight gain, adiposity, glucose tolerance or insulin sensitivity between HFD-fed WT and AMPK-MKO mice. In
both HFD-fed WT and AMPK-MKO mice, R419 enhanced insulin tolerance, insulin-stimulated glucose disposal, skeletal muscle 2-deoxyglucose
uptake, Akt phosphorylation and glucose transporter 4 (GLUT4) content independently of alterations in body mass. In WT, but not AMPK-MKO
mice, R419 improved treadmill running capacity. Treatment with R419 increased muscle electron transport chain content and activity in WT
mice; effects which were blunted in AMPK-MKO mice.
Conclusions: Treatment of obese mice with R419 improved skeletal muscle insulin sensitivity through a mechanism that is independent of
skeletal muscle AMPK. R419 also increases exercise capacity and improves mitochondrial function in obese WT mice; effects that are diminished
in the absence of skeletal muscle AMPK. These ﬁndings suggest that R419 may be a promising therapy for improving whole-body glucose
homeostasis and exercise capacity.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The AMP-activated protein kinase (AMPK) is an abg heterotrimer that
plays an important role in regulating whole-body glucose homeostasis
and insulin sensitivity (for review see Ruderman et al., 2013 [1] and
Steinberg & Jorgensen 2007 [2]). Over the last decade, many acti-
vators of AMPK have been shown to improve insulin sensitivity and
glycemic control [3e7] through AMPK dependent [8e10] and inde-
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found to exert its glucose lowering effects primarily by acting in the
liver (for review see Foretz et al., 2014 [14]). This liver predominant
effect of metformin is believed to be the result of high expression of
the organic cation transporter 1 (OCT1) that is required for metformin
uptake and thus limits the effectiveness of metformin to act in other
tissues such as skeletal muscle [14]. Similarly, direct activators of
AMPK like A769662 [15] and salicylate [16] activate AMPK through the
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Brief communicationmuscle [17,18]. While recent studies have identiﬁed new direct acti-
vators of AMPK that may be effective in muscle [19e21], their role in
regulating skeletal muscle insulin sensitivity and muscle mitochondrial
content is currently not known. As improvements in skeletal muscle
insulin sensitivity are important for restoring glucose homeostasis,
there is a need to develop and evaluate new activators of AMPK that
may exert positive effects on skeletal muscle metabolism and insulin
sensitivity.
In addition to improving insulin sensitivity, AMPK is also vital for
controlling muscle mitochondrial content and exercise capacity (for
review see Richter & Ruderman 2009 [22] and O’Neill et al., 2013
[23]). For example, mice with undetectable levels of AMPK activity due
to genetic deletion of a or b subunits in skeletal muscle have a
severely impaired capacity for treadmill running that is associated with
alterations in mitochondrial content and/or function [24,25]. In
contrast, the activation of AMPK through genetic manipulation or a
wide variety of pharmacological agents has been shown to increase
treadmill exercise performance in most studies [10,26e29]. These
data indicate that activators of AMPK may also be able to increase
muscle mitochondrial content and improve exercise performance.
R419 (N-(1-(4-cyanobenzyl)piperidin-4-yl)-6-(4-(4-methoxybenzoyl)
piperidine-1-carbonyl)nicotinamide) is a recently described mito-
chondrial complex I inhibitor that acutely activates AMPK in a variety of
cell systems including myotubes and hepatocytes [30]. R419 acutely
increases glucose uptake and fatty acid oxidation in cultured myotubes
via an AMPK dependent pathway. In contrast, R419 was shown to
acutely inhibit glucose production in isolated hepatocytes via an AMPK-
independent process. Metabolite tracer analysis of db/db mice treated
with R419 suggested increased ﬂux through both skeletal muscle
glycolytic and fatty acid oxidative pathways and increases in glucose
transporter 4 (GLUT4) promoter activity [30]. However, whether chronic
R419 treatment improves glucose homeostasis and insulin sensitivity
is not currently understood. Since the tissue speciﬁc uptake of R419
would not be limited by OCT1, as is the case with metformin, we
hypothesized that R419 would improve glucose homeostasis through
improvements in skeletal muscle insulin sensitivity and that this effect
would require skeletal muscle AMPK. Furthermore, since activation of
AMPK has been associated with muscle mitochondrial biogenesis, we
also hypothesized that R419 would increase exercise capacity through
an AMPK dependent process. We ﬁnd that in obese mice fed a high-fat
diet (HFD), R419 improves glucose tolerance and enhances insulin-
stimulated glucose disposal into skeletal muscle in WT and AMPK-
MKO mice while also enhancing exercise capacity only in WT controls.
2. MATERIAL AND METHODS
2.1. Mouse experiments
Male AMPK b1b2 ﬂoxed muscle creatine kinase (MCK)-Cre- (WT) and
AMPK b1b2 ﬂoxed MCK-Creþ (AMPK-MKO) littermates were used in
all experiments and have been described previously [25]. The
McMaster University (Hamilton, Canada) Animal Ethics Committee
approved all experimental protocols. To measure R419-mediated
AMPK activation, WT and AMPK-MKO mice were fasted for 12 h and
re-fed ad libitum with HFD (45 kcal% fat, D12451, Research Diets;
New Brunswick, NJ) formulated with R419 at a dose of 100 mg/kg HFD
(HFD þ R419) or the same HFD without R419. After 3 h of re-feeding,
blood glucose was measured by glucometer with a small nick of the
tail vein. Mice were then anesthetized and tibialis anterior (TA) muscle
was collected, snap frozen and kept at minus 80 C for later analysis.
To examine the chronic effects of R419 treatment, mice were main-
tained on a 12 h light/dark cycle and fed a HFD starting at 6e8 weeks644 MOLECULAR METABOLISM 4 (2015) 643e651  2015 TheAuthors. Published by Elsevier Gmbof age for 12 weeks. After the ﬁrst 6 weeks of HFD, mice were
continued on HFD or given HFD þ R419. Mice were allocated to
different experiments in order to reduce stress from excessive testing
and handling. Food intake was measured over a 72 h timeframe using
the Oxymax Lab Animal Monitoring System (Columbus Instruments,
OH).
2.2. Exercise capacity test
Mice were acclimated to the treadmill as described previously
[17,25,31]. Exercise capacity test was completed once after 5 weeks
of treatment. Mice began running at 8 m/min and treadmill speed was
increased by 1 m/min every 2 min as previously described [17,25]. At
exhaustion, time and speed were recorded and distance traversed
calculated. Exhaustion was deﬁned as the point at which instead of
running on the treadmill, mice remained on the shockers that serve to
encourage running for more than 10 s. Experimenters were unaware of
the genotype/treatment of the mice while they were performing the
experiment. Mice were quickly removed from the treadmill, blood was
collected by facial bleed, and blood glucose recorded. Lactate Assay
Kit was used to measure serum lactate, according to manufacturer
instructions (Biovision), in the fed basal state and at exhaustion.
2.3. Metabolic studies
After 6 weeks of treatment, computed tomography (CT) was used to
assess whole body adiposity and analyzed with the Amira Visage
Imaging Software Program, as described previously [10]. Mice were
fasted for 12 h in the evening andw100 mL of blood was collected by
facial bleed in the morning. Blood glucose concentrations were
recorded by glucometer. Serum analysis of insulin (Millipore) and non-
esteriﬁed free fatty acids (NEFA) (Wako NEFA-HR) were completed,
according to manufacturer instructions. For glucose (GTT, after 5
weeks of treatment) and insulin (ITT, after 6 weeks of treatment)
tolerance tests, mice were fasted for 6 h and injected with D-glucose
(1 g/kg) and human insulin (1 U/kg, NovoRapid), respectively. Blood
glucose was monitored during a 2 h span. Blood glucose was
measured by glucometer from a small nick of the tail vein.
Hyperinsulinemic-euglycaemic clamps were performed after 12 weeks
of the study as previously described [32,33]. The jugular vein was
surgically cannulated and if mice had <10% loss in body weight
change, they were clamped 5 days later. On the day of the clamp, mice
were fasted for 6 h and basal D- [3-3H]-glucose (7.5 mCi/h, 0.12 ml/h
in 0.9% saline) was infused for 1 h. This was followed by a constant
infusion of insulin (10 mU/kg/min insulin in 0.9% saline) (Novorapid),
containing D- [3-3H]-glucose (7.5 mCi/h, 0.12 ml/h in 0.9% saline).
Blood glucose was titrated with infusion of 50% dextrose that was
gradually increased until euglycaemia was reached, deﬁned as blood
glucose between 5.8 and 7.0 mmol/L for at least 30 min [32]. Addi-
tionally, glucose uptake in tissues was measured after intravenous
injection of 2-[14C]-deoxy-glucose (2-[14C] DG) (10 mCi). Blood sam-
ples were taken at 10, 20, and 30 min. Mice were euthanized with an
intravenous injection of ketamine-xylazine and sacriﬁced by exsan-
guination. Tissues were removed, snap frozen in liquid nitrogen, and
stored at minus 80 C for later analysis [10].
2.4. Analytical techniques
Extensor digitorum longus (EDL), TA and quadriceps muscles were
powdered on dry ice and homogenized in cell lysis buffer using a
Precellys 24 Homogenizer (Bertin Technologies; Paris, France). Lysates
were collected from centrifuged homogenate (13 000 rpm). Tissue-
speciﬁc glucose uptake (2-[14C] DG-Phosphate) was quantiﬁed by
scintillation counting in which the unphosphorylated 2-[14C] DGH. This is an open accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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fraction was subtracted from the total fraction of homogenate. Values
were expressed to blood glucose and 2-[14C] DG infusion in the blood.
Additionally, lysates were used to measure cytochrome c oxidase
(COX) activity, as described previously [34]. Blood was collected for
serum biochemistry measurements post-hyperinsulinemic euglycemic
clamp, including NEFA and insulin (Iso-insulin ELISA kit (Mercodia)).
Steele’s equation for steady state conditions was used to determine
rates of hepatic glucose output and glucose disposal in the basal and
clamped state [35]. Lipid content in quadriceps muscle was measured
by Bligh and Dyer procedure [36]. Brieﬂy, lipids were extracted using
chloroform and methanol. Lipids from chloroform phase were
saponiﬁed and glycerol content measured with Glycerol Reagent
(Sigma). Glycogen content was measured by incubating powdered
tissue in 6N HCl at 80 C and then neutralized with 6N NaOH. Glucose
content was measured using a Glucose Assay (Sigma).
2.5. Western blotting
SDS-PAGE system was used to separate protein extracts. Immuno-
blotting was performed once proteins were transferred on nitrocellu-
lose or polyvinylidene diﬂuoride membranes. Membranes were ﬁrst
blocked for 1 h at room temperature with 5% BSA in 1xTBST (Tris
buffered saline-Tween-20, 25 mM Tris$HCl (pH 7.5), 1 mM NaCl, and
0.1% Tween-20). Membranes were then incubated overnight at 4 C
with primary antibodies (from Cell Signaling, unless indicated) phos-
phorylated (p) acetyl-CoA carboxylase Ser79/212 (1:1000), ACC total
(1:1000), pAMPK Thr172 (1:1000), AMPK total (1:1000), pAkt Ser473
(1:1000), pAkt Thr308 (1:1000), Akt (1:1000), GLUT4 (Millipore,
1:1000), OXPHOS (Complex I subunit NDUFB8, Complex II subunit CII-
30, Complex III subunit Core 2 CIII-core2, Complex IV subunit I CIV-I,
and ATP synthase subunit alpha CV-alpha) (MitoSciences, 1:5000),
and GAPDH (Cell Signaling, 1:10 000) in TA and/or quadriceps muscle.
Membranes were then washed (3  5 min) with TBST and incubated
at room temperature for 1 h with corresponding secondary antibody.
Membranes were washed (3  5 min) with TBST and developed with
ClarityWestern ECL Substrate (Biorad). Densitometry was performed
using ImageJ software.
2.6. Statistical analysis
All results are expressed as mean standard error of the mean (SEM).
Results were analyzed using a two-way ANOVA with Bonferroni post-
hoc tests for group comparisons (unless otherwise denoted), using
GraphPad Prism software. Repeated measures ANOVA was used to
analyze body mass, GTT, ITT, and GIR. Signiﬁcance was accepted at
p  0.05.
3. RESULTS
3.1. R419 acutely activates skeletal muscle AMPK but does not
result in hypoglycemia
Treatment with R419 at 100 mg/kg HFD resulted in a plasma con-
centration of about 24 ng/mL and AUC of 600 ng*hr/mL over
24 h (Figure 1A), which is comparable to previous administration of
R419 (5e10 mg/kg body weight) by oral gavage [30]. In WT, but not
AMPK-MKO TA muscle, R419 resulted in a tendency for increased
AMPK Thr172 phosphorylation and signiﬁcant increases in ACC Ser79/
212 phosphorylation compared to HFD alone (Figure 1B). It should be
noted that ACC Ser79/212 phosphorylation is considered a more sen-
sitive measure of cellular AMPK activity as it takes into account the
signiﬁcant role that allosteric and covalent regulation of AMPK has on
its activity [37]. R419 treatment did not alter blood glucose in either WT
or AMPK-MKO mice relative to HFD alone (Figure 1C).MOLECULAR METABOLISM 4 (2015) 643e651  2015 The Authors. Published by Elsevier GmbH. This is an o
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not alter weight gain or adiposity in mice fed a HFD
Subsequent experiments were performed in WT and AMPK-MKO mice
chronically treated with HFD þ R419. A loss of skeletal muscle AMPK
did not exacerbate the development of HFD-induced obesity or weight
gain over time (Figure 1D). Treatment with HFD þ R419 did not result
in differences in weight gain (Figure 1D), food intake (Figure 1E) or
adiposity (Figure 1F) between groups. There was also no effect of R419
on liver, adipose tissue, soleus, or EDL mass (Table 1). We were
speciﬁcally interested in the effects of R419 in obesity, therefore, we
did not test the effects of the compound in control chow-fed mice but
the weight gain and adiposity obtained in these HFD-fed mice were
very comparable to our recent publications using the same HFD and
time course in which chow control mice were examined [33,38].
3.3. R419 improves insulin sensitivity independent of skeletal
muscle AMPK
HFD AMPK-MKO mice had comparable fasting blood glucose and in-
sulin levels compared to WT littermates irrespective of R419 treatment
(Figure 2A,B). AMPK-MKO mice had higher fasting serum NEFA
(Table 1). Glucose and insulin tolerance and corresponding areas under
the curve (AUC) were also similar between AMPK-MKO and WT lit-
termates fed a HFD (Figure 2C,D), indicating that a lack of AMPK does
not promote the dysregulation of glucose homeostasis. Of note, the
degree of glucose and insulin intolerance achieved in the HFD-fed mice
of this study was comparable to many previous studies from our
laboratory in which normal chow diet fed controls were also examined
in parallel [33,38].
Treatment of mice with R419 did not alter fasting blood glucose
(Figure 2A) but it did signiﬁcantly reduce fasting serum insulin in both
WT and AMPK-MKO mice (Figure 2B). Consistent with these ﬁndings,
R419 tended to improve glucose tolerance and signiﬁcantly increased
whole-body insulin tolerance in both WT and AMPK-MKO mice
(Figure 2C,D). These data indicate that R419 improves whole-body
insulin sensitivity in obese mice through a pathway independent of
skeletal muscle AMPK.
To examine the tissues contributing to these improvements in insulin
sensitivity, we conducted hyperinsulinemic-euglycaemic clamps. R419
treatment did not affect basal blood glucose or basal glucose turnover
(Supplementary Table 1). Clamped serum glucose and insulin levels
were comparable between groups (Supplementary Table 1). However,
R419 treatment increased insulin-stimulated glucose infusion rates
(GIR) in both WT and AMPK-MKO mice (Figure 2E,F). Consistent with an
elevated GIR, the insulin-stimulated glucose disposal rate (GDR) was
increased in both WT and AMPK-MKO mice treated with R419
(Figure 2G). Enhanced GDR with R419 treatment was accompanied by
elevated 2-[14C]DG uptake at the completion of the clamp into all
muscle types of both WT and AMPK-MKO mice (Figure 2H). There were
no differences between groups in circulating NEFA (Supplementary
Table 1), suggesting that adipose tissue insulin sensitivity was not
altered with R419 treatment. During the clamp, R419 treatment had a
modest effect on reducing hepatic glucose output (HGO) and tended to
increase the percent (%) suppression of HGO in WT mice
(Supplementary Table 1).
To investigate the intracellular mechanisms mediating enhanced
insulin-stimulated 2-[14C]DG uptake into muscle, we assessed Akt
phosphorylation and GLUT4 expression (Figure 2I). Improvements in
skeletal muscle insulin-stimulated glucose disposal with R419 treat-
ment were associated with enhanced phosphorylation of Akt Thr308
and Ser473 (Figure 2J,K). As AMPK may also increase insulin-
stimulated glucose uptake by increasing the transcription of GLUT4pen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 645
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Figure 1: R419 acutely activates skeletal muscle AMPK but does not induce hypoglycemia. A lack of skeletal muscle AMPK or R419 treatment does not alter weight
gain or adiposity in mice fed a HFD. (A) Plasma concentration of R419 when WT mice were given HFD þ R419 at a dose of 100 mg/kg HFD (n ¼ 5). (B) AMPK Thr172 relative to
AMPKa (from separate gels) (p ¼ 0.16) and ACC Ser79/212 relative to ACC (from separate gels) in TA muscle from WT and AMPK-MKO mice 3 h following HFD or HFD þ R419
administration. ND, not detectable. (C) Blood glucose concentrations 3 h following HFD or HFD þ R419 administration in WT and AMPK-MKO mice. (D) Body mass of HFD WT and
AMPK-MKO mice treated with or without R419 (two-way repeated measures ANOVA). (E) Food intake of HFD WT and AMPK-MKO mice treated with or without R419. (F) Measured
body percent adiposity with representative CT images. Highlighted red areas represent adipose region. Numbers within bars represent number of mice per group. Data are
expressed as means  SEM, *p < 0.05, for difference from HFD vs HFD þ R419, as assessed by student’s t-test (B).
Brief communicationthrough phosphorylation of histone deacetylases (HDACs) [39], we
examined skeletal muscle GLUT4 expression. R419 treatment
increased skeletal muscle GLUT4 protein expression in both WT and
AMPK-MKO mice (Figure 2L). These data indicate that R419 likely
increases glucose disposal in skeletal muscle by increasing both in-
sulin sensitivity and GLUT4 expression via pathways that are inde-
pendent of skeletal muscle AMPK.
3.4. R419 improves exercise capacity via an AMPK dependent
pathway
In agreement with our previous ﬁndings in chow-fed mice [25], time
and speed at exhaustion were signiﬁcantly impaired in AMPK-MKO
compared to WT mice (Figure 3A,B). Despite obtaining a much lower
maximal running speed, AMPK-MKO mice had elevated serum lactates
and displayed signiﬁcantly elevated blood glucose levels, consistent
with their inability to stimulate muscle glucose uptake during treadmill
running (Table 1), as previously reported [25]. R419 treatment
increased time to exhaustion, speed at exhaustion and distance
covered in WT but not AMPK-MKO mice (Figure 3A,B,C).
To examine the potential mechanism mediating these effects, we ﬁrst
assessed muscle glycogen and triglycerides and found that R419 did646 MOLECULAR METABOLISM 4 (2015) 643e651  2015 TheAuthors. Published by Elsevier Gmbnot affect these parameters (Table 1). In HFD-fed mice, mitochondrial
complex proteins were reduced in AMPK-MKO mice compared to WT
(Figure 3D). R419 increased the protein content of Complex II, III/IV,
and V of the respiratory chain in WT mice. These effects of R419 were
blunted in AMPK-MKO mice (Figure 3D). There was also a tendency for
increased protein expression of Complex I. R419 elevated COX activity
in quadriceps (quad) muscle of WT but not AMPK-MKO mice. Collec-
tively, these data suggest that R419 increases mitochondrial biogen-
esis (Figure 3E).
4. DISCUSSION
R419 has recently been shown to acutely activate AMPK in a variety of
cell systems [30] but its effects on whole-body glucose homeostasis,
insulin sensitivity and exercise capacity are not known. We demon-
strate that chronic R419 treatment lowered fasting insulin, improved
glucose tolerance and insulin-stimulated glucose disposal into skeletal
muscle, independently of alterations in adiposity in both WT and
AMPK-MKO mice. Increases in skeletal muscle 2-DG uptake were
associated with elevated Akt phosphorylation and increased GLUT4
expression. In addition, R419 treatment increased exercise capacityH. This is an open accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1 e Analysis of tissue weights, blood glucose, serum lactate, muscle glycogen and triglyceride and serum non-esteriﬁed free fatty acids (NEFA).
AMPK-WT AMPK-MKO
HFD HFDþR419 HFD HFDþR419
Average SEM N Average SEM N Average SEM N Average SEM N
Liver
Weight (mg) 1257.9 57.3 14 1192.4 124.4 9 1172.2 60.3 8 1230.0 78.53 8
Weight/gram bw (mg/g bw) 32.5 0.9 14 32.8 2.2 9 34.9 2.5 8 35.6 1.9 8
Epididymal adipose
Weight (mg) 1299.3 93.9 16 1224.1 104.4 12 1182.8 190.0 8 1173.4 119.9 9
Weight/gram bw (mg/g bw) 34.5 1.7 16 34.5 1.9 12 32.2 4.5 8 33.6 3.1 9
Soleus (mg) 11.4 0.4 13 11.7 0.3 7 11.6 0.5 8 10.9 0.5 7
EDL (mg) 11.0 0.5 9 11.6 0.5 7 10.9 0.9 8 11.2 0.4 7
Glucose (mmol/l)
Fed 9.1 0.4 13 8.4y 0.3 9 10.3x 0.6 11 9.2yx 0.5 6
Post-Exercise 11.6 0.6 10 9.5 0.5 8 12.5xx 1.2 10 10.3xx 0.4 6
Lactate (mmol/l)
Fed 6.5 1.0 10 9.3 1.5 7 8.3 1.0 4 8.4 2.2 5
Post-Exercise 8.6 0.8 11 8.1 0.9 7 11.0x 1.3 7 11.1x 0.4 5
Glycogen (mg/g tissue)
Quadriceps 137.3 6.4 16 141.3 9.8 8 124.9x 3.6 8 118.3x 10.3 8
Triglycerides (mg/g tissue)
Quadriceps 323.9 29.0 11 371.8 107.5 5 271.1 54.4 6 412.8 57.7 4
NEFA (mmol/l)
Fasting (12 h) 1.1 0.1 15 1.0 0.1 8 1.6xxx 0.1 6 1.4xxx 0.1 6
Data are expressed as means SEM, yp< 0.05, for difference from HFD control vs HFDþ R419, and xp< 0.05, xxp< 0.01, xxxp< 0.001 for difference from WT vs AMPK-MKO, as
determined by two-way ANOVA and Bonferroni post hoc test.and electron transport chain content and activity in WT, but not AMPK-
MKO mice. These data indicate that in the context of HFD-induced
obesity, R419 may be a promising therapy for improving exercise
capacity and glucose homeostasis.
Despite the well-documented role of AMPK activators improving insulin
sensitivity, most studies have found that mice having reductions in
skeletal muscle AMPK activity fed a control chow [25,34,40] or
obesity-promoting HFD diet [40,41] have normal skeletal muscle in-
sulin sensitivity compared to wildtype littermates; although it should be
noted that some studies have detected modest reductions in muscle
insulin sensitivity [17,42,43]. While previous studies have investigated
the effects of an obesity-inducing HFD on a genetic background of
lower muscle AMPK activity, it is possible that small amounts of re-
sidual AMPK activity may have been sufﬁcient to maintain skeletal
muscle insulin sensitivity in these previous reports [40,41]. Thus it was
unknown whether AMPK-MKO mice might be more susceptible to
HFD-induced obesity and insulin resistance. We found that body mass
and adiposity were comparable between genotypes. Insulin tolerance
was also unchanged between genotypes as were rates of glucose
infusion and glucose disposal during hyperinsulinemic-euglycemic
clamps. In contrast to our previous studies in young [25] and aged
[34] AMPK-MKO mice which had normal glucose tolerance, we found
that there was a tendency for AMPK-MKO mice to have improved
glucose tolerance and increased muscle GLUT4 expression when fed
HFD. We also found that the large reduction in muscle mitochondrial
content we have previously observed in chow-fed AMPK-MKO mice
[25] was largely attenuated (so that there were minimal genotype
differences) when mice were fed HFD. These data are consistent with
ﬁndings that HFD-induced mitochondrial biogenesis occurs via a
pathway involving calcium/calmodulin-dependent protein kinase [44].
Collectively, these data indicate that a lack of skeletal muscle AMPK
does not enhance the development of HFD-induced obesity or insulin
resistance and suggest that future studies investigating the induction
of compensatory pathways in AMPK-MKO mice in response to HFD are
warranted.MOLECULAR METABOLISM 4 (2015) 643e651  2015 The Authors. Published by Elsevier GmbH. This is an o
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irrespective of genotype. Notable improvements were also observed in
glucose and insulin tolerance with R419 treatment. Hyperinsulinemic-
euglycaemic clamps revealed that improved insulin sensitivity was
mediated by enhanced insulin-stimulated glucose disposal into skel-
etal muscle and that this effect was independent of skeletal muscle
AMPK. In addition to enhancing insulin-stimulated skeletal muscle
glucose uptake in a skeletal muscle AMPK independent manner, R419
modestly reduced insulin-stimulated hepatic glucose output; however,
it should be noted that the insulin-simulated % suppression of HGO
was not signiﬁcantly different between treatments. Given the modest
effect on HGO (and lack of a signiﬁcant increase in the % suppression),
these data suggest, that, in contrast to metformin that primarily elicits
its insulin sensitizing effects by acting in the liver [33,45], R419 pri-
marily elicits its glucose lowering/insulin sensitizing effects by
enhancing skeletal muscle glucose uptake.
In order to assess the potential mechanisms contributing to the
improved insulin-stimulated glucose disposal/2-DG uptake into skel-
etal muscle following R419 treatment, we assessed activating phos-
phorylation of Akt and total GLUT4 expression. We found that R419
treated mice had greater Akt phosphorylation and increased GLUT4
expression compared to HFD-fed mice. The overexpression of GLUT4
in skeletal muscle enhances insulin-stimulated glucose uptake and
reduces fasting insulin in HFD-fed mice [46]. Enhanced GLUT4
expression may also alter hepatic glucose metabolism/insulin sensi-
tivity, thus explaining the potentially modest changes observed in liver
insulin sensitivity [47]. This suggests that increased glucose disposal
in skeletal muscle via R419 may be mediated in part through increases
in GLUT4 expression via AMPK-independent pathways. These ﬁndings
are consistent with reports that GLUT4 expression is also increased
following exercise via AMPK-independent pathways [48,49]. Future
studies investigating the AMPK-independent mechanisms controlling
GLUT4 transcription are warranted.
Exercise training is associated with the induction of mitochondrial
biogenesis and enhanced exercise performance (for review see Richterpen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 647
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Figure 2: R419 improves insulin sensitivity and insulin-stimulated glucose disposal in skeletal muscle. (A) 12 h fasting blood glucose. (B) 12 h fasting serum insulin. (C) Glucose tolerance test (GTT) and GTT AUC. (D) Insulin tolerance
test (ITT) and ITT AUC. (E) Glucose infusion rate (GIR) curve and clamped GIR. (F) Blood glucose concentration curve during clamp. (G) Glucose disposal rate (GDR). (H) 2-[14C]DG uptake in TA, EDL, and quadriceps (quad) muscle in WT and AMPK-
MKO mice treated with or without R419. (I) Representative western blots of pAkt Ser473, pAkt Ser308, total Akt, GLUT4, and GAPDH. (J) Protein expression of pAkt Ser473 relative to Akt (from separate gels). (K) Protein expression pAkt Thr308
relative to Akt (from separate gels). (L) Protein expression of GLUT4 relative to GAPDH. Numbers within bars represent number of mice per group. Data are expressed as means  SEM, yp < 0.05, yyp < 0.01, yyyp < 0.001 for difference from
HFD control vs HFD þ R419, as determined by two-way ANOVA and Bonferroni post hoc test; zp < 0.05, zzp < 0.01, zzzp < 0.001 for difference between HFD WT and HFD þ R419 WT, and {p < 0.05, {{{p < 0.001 for difference between HFD
AMPK-MKO and HFD þ R419 MKO, as determined by two-way repeated measures ANOVA and Bonferroni post hoc test (C,D,E,F).
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Figure 3: R419 improves exercise capacity via an AMPK dependent pathway involving increased content and activity of the electron transport chain. (A) Time to
exhaustion. Signiﬁcant interaction between treatment and genotype (p ¼ 0.03). (B) Speed at exhaustion. Signiﬁcant interaction between treatment and genotype (p ¼ 0.02). (C)
Distance traversed. Signiﬁcant interaction between treatment and genotype (p ¼ 0.02). (D) OXPHOS complex expression in quadriceps muscle. Representative image of OXPHOS
blot from the same membrane. (E) COX Activity. Data are expressed as means  SEM, yp < 0.05, yyp < 0.01 for difference from HFD control vs HFD þ R419; *p < 0.05 for
difference from HFD control post hoc within genotype; xp < 0.05, xxp < 0.01, xxxp < 0.001 for difference from WT vs AMPK-MKO, as determined by two-way ANOVA and
Bonferroni post hoc test.& Ruderman 2009 [22] and O’Neill et al., 2011 [23]). R419 improved
treadmill running capacity in WT mice by over 30%, while having no
effect in AMPK-MKO mice. This increase in treadmill running capacity
is comparable to other studies in mice with endurance exercise
training [50,51]. A limitation of our study was that we deﬁned fatigue/
exhaustion as the point at which instead of running on the treadmill,
mice remained on the shockers, which serve to encourage running, for
more than 10 s. Future studies measuring biochemical measures of
exhaustion ([52], e.g. muscle and liver glycogen, lactate) with and
without R419 and/or muscle AMPK deﬁciency will be important to
establish genuine fatigue and to conﬁrm the effects were not due to
changes in motivation or altered sensitivity to the electrical shocking
system.
A feature of studies in which AMPK has been activated using either
genetic gain of function [53] or pharmacological agents such as AICAR
[54] is that muscle glycogen contents are elevated; which could be a
primary factor contributing to the enhanced exercise performance [42].
With R419 treatment, there was no change in muscle glycogen content.
Instead, improvements in treadmill running capacity in WT mice were
associated with increased protein expression of subunits of the electron
transport chain and COX activity. These observations that R419, a
complex-I inhibitor, can enhance mitochondrial content and function
are consistent with previous ﬁndings indicating that siRNA mediated
complex-1 inhibition in C. elegans induces mitohormesis (an increase in
mitochondrial biogenesis and efﬁciency) [55]. Interestingly, these ef-
fects were blunted in AMPK-MKO mice suggesting that R419 primarily
elicits its effects on mitochondrial function through a pathway involving
AMPK. Future studies investigating the downstream substrates medi-
ating R419 effects on mitochondrial function are warranted.
In summary, chronic treatment with R419 leads to substantial im-
provements in glucose homeostasis, effects that are primarilyMOLECULAR METABOLISM 4 (2015) 643e651  2015 The Authors. Published by Elsevier GmbH. This is an o
www.molecularmetabolism.commediated through enhanced skeletal muscle insulin sensitivity and are
independent of skeletal muscle AMPK. In addition, chronic treatment of
obese mice with R419 elicits improvements in exercise capacity and
skeletal muscle electron transport chain content/activity in WT mice,
effects which are blunted in the absence of AMPK. These data indicate
that R419 mimics many of the effects of chronic exercise training in
skeletal muscle and suggest that R419 may be of therapeutic
importance for improving exercise capacity and skeletal muscle insulin
sensitivity in obesity.
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